Literature DB >> 19935673

Quantified gene expression levels for phase I/II metabolizing enzyme and estrogen receptor levels in benign prostate from cohorts designated as high-risk (UK) versus low-risk (India) for adenocarcinoma at this organ site: a preliminary study.

Paras B Singh1, Narasimhan Ragavan, Katherine M Ashton, Prabir Basu, Sayeed M Nadeem, Caroline M Nicholson, R K Gopala Krishna, Shyam S Matanhelia, Francis L Martin.   

Abstract

Risk of clinically significant prostate adenocarcinoma (CaP) varies worldwide, although there is a uniform prevalence of latent disease. A hormone-responsive tissue, the prostate possesses the metabolizing capacity to biotransform a variety of environmental procarcinogens or endogenous hormones. Whether such metabolizing capacity or estrogen receptor (ER) status underlies these demographic differences in susceptibility to CaP remains unclear. With appropriate ethical permission, verified-benign tissues were obtained following transurethral resection of the prostate from a high-risk region (n = 12 UK-resident Caucasians) and a typically low-risk region (n = 14 India-resident Asians). Quantitative gene expression analysis was employed for cytochrome P450 (CYP)1B1, N-acetyltransferase (NAT)1, NAT2, catechol-O-methyl transferase (COMT), sulfotransferase (SULT)1A1, ERalpha, ERbeta and aromatase (CYP19A1). To quantify the presence or absence of CYP1B1, ERalpha or ERbeta, and to identify their in situ localization, immunohistochemistry was carried out. The two cohorts had reasonably well-matched serum levels of prostate-specific antigen or hormones. Expression levels for the candidate genes investigated were similar. However, clear differences in protein levels for CYP1B1 and ERbeta were noted. Staining for CYP1B1 tended to be nuclear-associated in the basal glandular epithelial cells, and in UK-resident Caucasian tissues was present at a higher (P = 0.006) level compared with that from India-resident Asians. In contrast, a higher level of positive ERbeta staining was noted in prostates from India-resident Asians. These study findings point to differences in metabolizing capacity and ER status in benign prostate tissues that might modulate susceptibility to the emergence of clinically significant CaP in demographically distinct populations.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19935673      PMCID: PMC3739086          DOI: 10.1038/aja.2009.71

Source DB:  PubMed          Journal:  Asian J Androl        ISSN: 1008-682X            Impact factor:   3.285


  41 in total

1.  Comparative studies of the estrogen receptors beta and alpha and the androgen receptor in normal human prostate glands, dysplasia, and in primary and metastatic carcinoma.

Authors:  I Leav; K M Lau; J Y Adams; J E McNeal; M E Taplin; J Wang; H Singh; S M Ho
Journal:  Am J Pathol       Date:  2001-07       Impact factor: 4.307

2.  Human CYP1B1 and anticancer agent metabolism: mechanism for tumor-specific drug inactivation?

Authors:  B Rochat; J M Morsman; G I Murray; W D Figg; H L McLeod
Journal:  J Pharmacol Exp Ther       Date:  2001-02       Impact factor: 4.030

3.  Role of human cytochrome P450 1A1, 1A2, 1B1, and 3A4 in the 2-, 4-, and 16alpha-hydroxylation of 17beta-estradiol.

Authors:  A F Badawi; E L Cavalieri; E G Rogan
Journal:  Metabolism       Date:  2001-09       Impact factor: 8.694

4.  Metabolic activation of carcinogens and expression of various cytochromes P450 in human prostate tissue.

Authors:  J A Williams; F L Martin; G H Muir; A Hewer; P L Grover; D H Phillips
Journal:  Carcinogenesis       Date:  2000-09       Impact factor: 4.944

Review 5.  Endogenous estrogens as carcinogens through metabolic activation.

Authors:  J D Yager
Journal:  J Natl Cancer Inst Monogr       Date:  2000

6.  Evaluation of androgen, estrogen (ER alpha and ER beta), and progesterone receptor expression in human prostate cancer by real-time quantitative reverse transcription-polymerase chain reaction assays.

Authors:  A Latil; I Bièche; D Vidaud; R Lidereau; P Berthon; O Cussenot; M Vidaud
Journal:  Cancer Res       Date:  2001-03-01       Impact factor: 12.701

Review 7.  A potential paradox in prostate adenocarcinoma progression: oestrogen as the initiating driver.

Authors:  Paras B Singh; Shyam S Matanhelia; Francis L Martin
Journal:  Eur J Cancer       Date:  2008-04-01       Impact factor: 9.162

8.  Cancer incidence rates among South Asians in four geographic regions: India, Singapore, UK and US.

Authors:  Tanuja Rastogi; Susan Devesa; Punam Mangtani; Aleyamma Mathew; Nicola Cooper; Roy Kao; Rashmi Sinha
Journal:  Int J Epidemiol       Date:  2007-12-19       Impact factor: 7.196

9.  Suppression of androgen receptor signaling and prostate specific antigen expression by (-)-epigallocatechin-3-gallate in different progression stages of LNCaP prostate cancer cells.

Authors:  Chih-Pin Chuu; Rou-Yu Chen; John M Kokontis; Richard A Hiipakka; Shutsung Liao
Journal:  Cancer Lett       Date:  2008-11-01       Impact factor: 8.679

10.  Quantification of phase I/II metabolizing enzyme gene expression and polycyclic aromatic hydrocarbon-DNA adduct levels in human prostate.

Authors:  Kaarthik John; Narasimhan Ragavan; M Margaret Pratt; Paras B Singh; Salah Al-Buheissi; Shyam S Matanhelia; David H Phillips; Miriam C Poirier; Francis L Martin
Journal:  Prostate       Date:  2009-04-01       Impact factor: 4.104

View more
  7 in total

1.  The clinicopathological and prognostic role of thrombocytosis in patients with cancer: A meta-analysis.

Authors:  Xiaojing Zhang; Zunfu Lv; Hua Yu; Jianqing Zhu
Journal:  Oncol Lett       Date:  2017-04-20       Impact factor: 2.967

2.  Prostate cancer risk and aggressiveness associated with the CYP1B1 4326C/G (Leu432Val) polymorphism: a meta-analysis of 2788 cases and 2968 controls.

Authors:  Jie Yang; Dong-Liang Xu; Qiang Lu; Zhi-Jian Han; Jun Tao; Pei Lu; Chao Wang; Xiao-Ke Di; Min Gu
Journal:  Asian J Androl       Date:  2012-04-16       Impact factor: 3.285

3.  Association of CYP1B1 Polymorphisms with Breast Cancer: A Case-Control Study in the Han Population in Ningxia Hui Autonomous Region, P. R. China.

Authors:  Haiyan Jiao; Chunlian Liu; Weidong Guo; Liang Peng; Yintao Chen; Francis L Martin
Journal:  Biomark Insights       Date:  2010-02-12

4.  Elevated oestrogen receptor splice variant ERαΔ5 expression in tumour-adjacent hormone-responsive tissue.

Authors:  Siân E Taylor; Imran I Patel; Paras B Singh; Caroline M Nicholson; Helen F Stringfellow; R K Gopala Krishna; Shyam S Matanhelia; Pierre L Martin-Hirsch; Francis L Martin
Journal:  Int J Environ Res Public Health       Date:  2010-11-02       Impact factor: 3.390

5.  CYP1B1 enhances the resistance of epithelial ovarian cancer cells to paclitaxel in vivo and in vitro.

Authors:  Zhuangyan Zhu; Yaqin Mu; Caixia Qi; Jian Wang; Guoping Xi; Juncheng Guo; Ruoran Mi; Fuxi Zhao
Journal:  Int J Mol Med       Date:  2014-12-16       Impact factor: 4.101

6.  CYP1B1 Enhances Cell Proliferation and Metastasis through Induction of EMT and Activation of Wnt/β-Catenin Signaling via Sp1 Upregulation.

Authors:  Yeo-Jung Kwon; Hyoung-Seok Baek; Dong-Jin Ye; Sangyun Shin; Donghak Kim; Young-Jin Chun
Journal:  PLoS One       Date:  2016-03-16       Impact factor: 3.240

Review 7.  Carcinogens and DNA damage.

Authors:  Jessica L Barnes; Maria Zubair; Kaarthik John; Miriam C Poirier; Francis L Martin
Journal:  Biochem Soc Trans       Date:  2018-10-03       Impact factor: 5.407

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.